Abstract 272P
Background
Epirubicin (EPI) is a first-line chemotherapeutic drug for the clinical treatment of diffuse large B cell lymphoma (DLBCL), but the overexpression of multidrug resistance (MDR) transporter proteins, such as P-glycoprotein (P-gp), renders EPI ineffective. On the basis of some studies, melatonin (MLT) is considered to possess the potential for chemotherapeutic synergy that can be leveraged to overcome MDR.
Methods
The human DLBCL cells SUDHL-6 and SUDHL-10 were incubated with MLT and/or EPI for 48 h. Using CCK8 assay, the cell viability of SUDHL-10 and SUDHL-6 cell lines under different treatments were tested. Using AO/EB assay ,the apoptosis of SUDHL-6 cell line was detected. Cytochrome c release experiment was used to reveal the further molecular mechanism. Immunofluorescence experiment was used to detect the expression of P-gp of DLBCL cell lines under different drug treatment groups. Rhodamine-123 and epirubicin accumulation test were used to detect the function of P-gp. Immunohistochemical staining studies in tumor tissue of DLBCL disclosed that the expression of P-gp and P65. Western blotting assay and pulldown assay were used to detect the relationship between NF-κB pathway and P-gp exression.
Results
Melatonin potentiated the epirubicin-mediated inhibition of cell proliferation and increased epirubicin-induced apoptosis. Melatonin inhibits epirubicin-induced P-glycoprotein expression and the activity of the P-glycoprotein pump.Epirubicin promotes the expression of P-gp by activating the NF-κB pathway. However, melatonin inhibited the epirubicin-mediated activation of NF-κB signaling and the expression of P-gp.
Conclusions
Our results demonstrated that MLT inactivating the NF-κB pathway and down-regulating the expression of P-gp, ultimately sensitized EPI-mediated growth suppression of DLBCL cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The second hospital of Dalian medical university.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
YO31 - Primary pulmonary sarcoma
Presenter: Khilola Ubaydullaeva
Session: Poster display session
Resources:
Abstract
YO32 - prostatic rhabdomyosarcoma in an adult patient: A case study
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
YO33 - Hyponatremia – slaying the dragon or chasing a mirage- a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO34 - A rare endocrinological syndrome presenting with weakness in Soft tissue sarcoma - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO35 - Gefitinib induced movement disorder - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO36 - A case of BRAF V600E mutated non-small-cell lung cancer with pleomorphic features
Presenter: Reiko Matsuzawa
Session: Poster display session
Resources:
Abstract
YO37 - Intraventricular metastasis as the first presentation of non-small cell lung cancer
Presenter: Siraphong Putraveephong
Session: Poster display session
Resources:
Abstract
YO38 - Cerebral metastases from a thymic malignancy: a case report
Presenter: Marfu'au Nik Eezamuddeen
Session: Poster display session
Resources:
Abstract
YO39 - Primary Follicular Thyroid Carcinoma Metastatic to the Kidney Mimicking Renal Cell Carcinoma: A Case Report
Presenter: Jestoni Aranilla
Session: Poster display session
Resources:
Abstract
YO40 - A Rare Case of Primary Malignant Giant Cell Tumor of Tibia
Presenter: Gowthami Venugopal
Session: Poster display session
Resources:
Abstract